Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001532
Publisher
BMJ
Online
2020-12-24
DOI
10.1136/jitc-2020-001532
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 study of pembrolizumab in patients with advanced rare cancers
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
- (2020) Camille Duhamel et al. Journal of Personalized Medicine
- Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes
- (2019) Garima Yagnik et al. Oncotarget
- Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab
- (2019) Mario Caccese et al. ANTI-CANCER DRUGS
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The natural course of hypermutator gliomas.
- (2018) Carlos Kamiya-Matsuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
- (2017) Keiko Kitajima et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
- (2016) Marisa Dolled-Filhart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Eukaryotic Mismatch Repair in Relation to DNA Replication
- (2015) Thomas A. Kunkel et al. Annual Review of Genetics
- Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas
- (2015) Jian-Qiang Lu et al. ENDOCRINE PATHOLOGY
- Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment
- (2015) Mizuki Nishino et al. EUROPEAN JOURNAL OF RADIOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- The epidemiology and genetics of pituitary adenomas
- (2009) Adrian F. Daly et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started